ZEMAIRA

Serial Number 99036259
688

Registration Progress

Application Filed
Feb 11, 2025
Under Examination
Jun 17, 2025
Approved for Publication
Apr 22, 2025
Published for Opposition
Apr 22, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Dec 17, 2025 140 days

Trademark Image

ZEMAIRA

Basic Information

Serial Number
99036259
Filing Date
February 11, 2025
Published for Opposition
April 22, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jun 17, 2025
Application
Pending
Classes
005

Rights Holder

CSL Behring L.L.C.

16
Address
1020 First Avenue
King of Prussia, PA 19406

Ownership History

CSL Behring L.L.C.

Original Applicant
16
King of Prussia, PA

CSL Behring L.L.C.

Owner at Publication
16
King of Prussia, PA

Legal Representation

Attorney
Scott Woldow

USPTO Deadlines

Next Deadline
140 days remaining
NOA E-Mailed - SOU Required
Due Date
December 17, 2025
Extension Available
Until June 17, 2026

Application History

9 events
Date Code Type Description Documents
Jun 17, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 22, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 22, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 16, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 22, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 11, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 11, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Feb 11, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 11, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations to treat deficiencies of Alpha One Proteinase inhibitors; Pharmaceutical preparations for transplant conditions; Pharmaceutical preparations for renal conditions; Pharmaceutical preparations for treatment of rejection in transplant recipients; Pharmaceutical preparations for antibody rejection conditions; Pharmaceutical preparations for treatment of emphysema, lung conditions, anti-inflammatory conditions, immunological conditions, and protein deficiencies; Pharmaceutical preparations to prevent and treat graft vs. host disease; Pharmaceutical preparations for prevention and treatment of Primary Graft Dysfunction

Classification

International Classes
005